CHICAGO, Oct. 23, 2014 /PRNewswire/ -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Edwards Lifesciences Corp. (NYSE:EW-Free Report), Hospira Inc. (NYSE:HSP-Free Report), Hologic Inc. (Nasdaq:HOLX-Free Report) and Heartware International Inc. (Nasdaq:HTWR-Free Report).
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.
Here are highlights from Wednesday's Analyst Blog:
Can Edwards Lifesciences Surprise on Earnings in Q3?
Medical instruments giant, Edwards Lifesciences Corp. (NYSE:EW-Free Report), is slated to report its third-quarter 2014 earnings results on Oct 23. Last quarter, the company had posted a 14.3% positive surprise.
Moreover, Edwards Lifesciences has delivered positive earnings surprises in all the past four quarters with an average beat of 9.7%. Let's see how things are shaping up for this announcement.
Factors at Play
In the second quarter, Edwards successfully launched its non-invasive monitoring technology – the ClearSight system – in the U.S. The company anticipates positive adoption of this system resulting in substantial sales.
This, in turn, is expected to significantly benefit the company's critical care product line in the coming quarters of 2014. This induced management to raise underlying sales growth expectation for the segment at the second quarter conference call.
Currently, the company is engaged in replacing SAPIEN by SAPIEN XT – the latest in the SAPIEN family of valves – in the hospitals, which is used to treat high-risk and inoperable heart patients. The company expects most of this process to be over by the end of the third quarter. We believe this conversion will expand Edwards' customer base reaching out to a greater number of heart patients, thereby enhancing Edwards' profitability, which is expected to be reflected in the coming two quarterly earnings results.
The fact that rival major Medtronic's CoreValve has been granted U.S. FDA approval in Jan 2014 poses concern, given that the medical devices industry is a highly competitive space. However, with the recent and timely FDA approval of the comparable next-generation transcatheter valve SAPIEN XT, Edwards is currently well positioned to continue dominating and strengthening its foothold in the U.S. transcatheter aortic heart valve market.
For the third quarter of 2014, Edwards expects total sales in the range of $530–$570 million and adjusted earnings per share of 66–72 cents. The Zacks Consensus Estimate for revenues of $544 million lies within the company's guidance while the same for earnings of 72 cents coincides with the upper limit of the company's guided range.
Earnings Whispers?
Our proven model does not conclusively show that Edwards is likely to beat earnings this quarter. That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1, 2 or 3 for this to happen. That is not the case here as you will see below.
Zacks ESP: Edwards has an earnings ESP of 0.00%. That is because both the Most Accurate estimate and the Zacks Consensus Estimate stand at 72 cents.
Zacks Rank: Edwards has a Zacks Rank #2 (Buy) which increases the predictive power of ESP. However, a 0.00% ESP makes surprise prediction difficult.
On the other hand, we caution against stocks with Zacks Rank #4 and 5 (Sell-rated stocks) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Stocks to Consider
Here are some companies you may want to consider as our model shows they have the right combination of elements to post an earnings beat this quarter:
Hospira Inc. (NYSE:HSP-Free Report), earnings ESP of +7.55% and a Zacks Rank #3 (Hold).
Hologic Inc. (Nasdaq:HOLX-Free Report), earnings ESP of +5.41% and a Zacks Rank #3.
Heartware International Inc. (Nasdaq:HTWR-Free Report), earnings ESP of +21.21% and Zacks Rank #3.
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today.
About Zacks
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978. The later formation of the Zacks Rank, a proprietary stock picking system; continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros.
Get the full Report on EW - FREE
Get the full Report on HSP - FREE
Get the full Report on HOLX - FREE
Get the full Report on HTWR - FREE
http://www.zacks.com/registration/pfp/?ALERT=ZR_LINK&adid=PR_AB&d_alert=rd_final_rank&t=MSFT
Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
[email protected]
http://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Logo - http://photos.prnewswire.com/prnh/20101027/ZIRLOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/the-zacks-analyst-blog-highlights-edwards-lifesciences-hospira-hologic-and-heartware-international-294840094.html
SOURCE Zacks Investment Research, Inc.
Share this article